U.S. flag

An official website of the United States government

NM_001184880.2(PCDH19):c.1549G>A (p.Ala517Thr) AND Developmental and epileptic encephalopathy, 9

Germline classification:
Uncertain significance (2 submissions)
Last evaluated:
Jan 22, 2024
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001089700.5

Allele description [Variation Report for NM_001184880.2(PCDH19):c.1549G>A (p.Ala517Thr)]

NM_001184880.2(PCDH19):c.1549G>A (p.Ala517Thr)

Gene:
PCDH19:protocadherin 19 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Xq22.1
Genomic location:
Preferred name:
NM_001184880.2(PCDH19):c.1549G>A (p.Ala517Thr)
HGVS:
  • NC_000023.11:g.100407049C>T
  • NG_021319.1:g.8225G>A
  • NM_001105243.2:c.1549G>A
  • NM_001184880.2:c.1549G>AMANE SELECT
  • NM_020766.3:c.1549G>A
  • NP_001098713.1:p.Ala517Thr
  • NP_001171809.1:p.Ala517Thr
  • NP_065817.2:p.Ala517Thr
  • LRG_843t1:c.1549G>A
  • LRG_843:g.8225G>A
  • LRG_843p1:p.Ala517Thr
  • NC_000023.10:g.99662047C>T
  • NC_000023.10:g.99662047C>T
  • NM_001184880.1:c.1549G>A
  • p.Ala517Thr
Protein change:
A517T
Links:
dbSNP: rs778072039
NCBI 1000 Genomes Browser:
rs778072039
Molecular consequence:
  • NM_001105243.2:c.1549G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001184880.2:c.1549G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_020766.3:c.1549G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Developmental and epileptic encephalopathy, 9 (DEE9)
Synonyms:
EPILEPSY, FEMALE-RESTRICTED, WITH MENTAL RETARDATION; JUBERG-HELLMAN SYNDROME; PCDH19-Related X-Linked Female-Limited Epilepsy with Mental Retardation; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0010246; MedGen: C1848137; Orphanet: 2076; OMIM: 300088

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001245183Laboratory of Inherited Metabolic Diseases, Research centre for medical genetics
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(Feb 14, 2020)
unknownclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV002107571Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Jan 22, 2024)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing
not providedunknownyesnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

[Clinical and genetic characteristics of epilepsy caused by mutations in the PCDH19 gene (OMIM: 300088)].

Dadali EL, Mishina IA, Borovikov AO, Sharkov AA, Kanivets IV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(1):55-61. doi: 10.17116/jnevro202012001155. Russian.

PubMed [citation]
PMID:
32105270
See all PubMed Citations (4)

Details of each submission

From Laboratory of Inherited Metabolic Diseases, Research centre for medical genetics, SCV001245183.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownyesnot providednot providednot providednot providednot providednot providednot provided

From Labcorp Genetics (formerly Invitae), Labcorp, SCV002107571.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 517 of the PCDH19 protein (p.Ala517Thr). This variant is present in population databases (rs778072039, gnomAD 0.002%). This missense change has been observed in individual(s) with PCDH19-related conditions (PMID: 32105270, 36011376). ClinVar contains an entry for this variant (Variation ID: 870165). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on PCDH19 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 20, 2024